Wave Life Sciences Highlights Pipeline Progress and Expansion Leveraging New PN Backbone Chemistry Modifications
11 janv. 2021 08h00 HE
|
Wave Life Sciences USA, Inc.
Three clinical trials to begin in 2021 with compounds containing Wave’s novel PN backbone chemistry modifications Data from ongoing PRECISION-HD and OLE clinical trials for Huntington’s disease...
Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer
02 déc. 2020 08h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Highlight Preclinical ADAR Editing Data and Neurology Programs at TIDES and OTS Annual Meetings
15 sept. 2020 07h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
10 sept. 2020 16h25 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
14 août 2020 08h30 HE
|
Vaccinex, Inc.
On track to report potentially pivotal Phase 2 Huntington’s disease topline data by early October Phase 1/2 trial of pepinemab in Alzheimer’s disease to begin enrolling patients in September Raised...
Wave Life Sciences Reports Second Quarter 2020 Financial Results and Provides Business Update
10 août 2020 07h30 HE
|
Wave Life Sciences USA, Inc.
Data from 32 mg cohorts of both PRECISION-HD trials and PRECISION-HD OLE trials expected in 1Q 2021 C9orf72 and SNP3 clinical trial applications on track to be submitted in 4Q 2020 ADAR editing...
Wave Life Sciences to Webcast Conference Call of Second Quarter 2020 Financial Results on August 10, 2020
27 juil. 2020 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 27, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s Disease
19 juin 2020 07h05 HE
|
uniQure Inc.
LEXINGTON, Mass. and AMSTERDAM, June 19, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
Wave Life Sciences to Present at the Jefferies 2020 Virtual Healthcare Conference
26 mai 2020 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Appoints Dr. Ken Rhodes as Senior Vice President, Therapeutics Discovery
18 mai 2020 07h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., May 18, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...